Chelation Therapy’s Dramatic Effects, Part 1

Remember the big story about 2014’s TACT Study (the Trial to Assess Chelation Therapy)? Well, in light of its success, now there’s going to be a followup study, TACT 2. Dr. Tony Lamas, the TACT Director, joins us to discuss the implications of the original TACT Study, and what we can expect from TACT 2. The results of TACT were a surprise to the medical community—they strongly suggest that intravenous chelation with EDTA can reduce the risk of subsequent cardiac events in heart attack sufferers. The protective effect was particularly dramatic in diabetic patients. Why were the results greeted with such skepticism? Why isn’t chelation now being embraced by the medical community? Now that we know chelation works, do we know how? What additional information is being sought in TACT 2? What insights does TACT bring us for our understanding of how environmental heavy metals like lead and cadmium promote disease? Were the vitamins that patients took in the TACT Study beneficial? Click HERE for part 2.